Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Pneumonia in Patients with Chronic Obstructive Pulmonary Disease

  • Restrepo, Marcos I. (South Texas Veterans Health Care System) ;
  • Sibila, Oriol (Servei de Pneumologia, Hospital de la Santa Creu i Sant Pau) ;
  • Anzueto, Antonio (South Texas Veterans Health Care System)
  • Received : 2018.03.28
  • Accepted : 2018.04.01
  • Published : 2018.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Chronic obstructive pulmonary disease (COPD) is a frequent comorbid condition associated with increased morbidity and mortality. Pneumonia is the most common infectious disease condition. The purpose of this review is to evaluate the impact of pneumonia in patients with COPD. We will evaluate the epidemiology and factors associated with pneumonia. We are discussing the clinical characteristics of COPD that may favor the development of infections conditions such as pneumonia. Over the last 10 years, there is an increased evidence that COPD patients treated with inhaled corticosteroids are at increased risk to develp pneumonia. We will review the avaialbe information as well as the possible mechanism for this events. We also discuss the impact of influenza and pneumococcal vaccination in the prevention of pneumonia in COPD patients.

Keywords

References

  1. Heron M. Deaths: leading causes for 2010. Natl Vital Stat Rep 2013;62:1-96.
  2. National Heart, Lung, and Blood Institute. Data fact sheet. Chronic obstructive pulmonary disease. Bethesda, MD: U.S. Department of Health and Human Services; 2003.
  3. World Health Organization. The top 10 causes of death [Internet]. Geneva: World Health Organization; 2017 [cited 2017 Nov 10]. Available from: http://www.who.int/media-centre/factsheets/fs310/en.
  4. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 2015;373:415- 27. https://doi.org/10.1056/NEJMoa1500245
  5. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012;67:71-9. https://doi.org/10.1136/thx.2009.129502
  6. CDC/National Center for Health Statistics. Number and rate of discharges from short-stay hospitals and of days of care, with average length of stay and standard error, by selected first-listed diagnostic categories: United States, 2010 [Internet]. Atlanta: CDC/NCHS National Hospital Discharge Survey; 2010 [cited 2017 Nov 10]. Available from: http://www.cdc.gov/nchs/data/nhds/2average/2010ave2_firstlist.pdf.
  7. Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2010. National Vital Statistics Reports [Internet]. Hyattsville: National Center for Health Statistics; 2013 [cited 2017 Nov 10]. Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_04.pdf.
  8. Ruiz M, Ewig S, Marcos MA, Martinez JA, Arancibia F, Mensa J, et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 1999;160:397-405. https://doi.org/10.1164/ajrccm.160.2.9808045
  9. Farr BM, Bartlett CL, Wadsworth J, Miller DL. Risk factors for community-acquired pneumonia diagnosed upon hospital admission. British Thoracic Society Pneumonia Study Group. Respir Med 2000;94:954-63. https://doi.org/10.1053/rmed.2000.0865
  10. Farr BM, Sloman AJ, Fisch MJ. Predicting death in patients hospitalized for community-acquired pneumonia. Ann Intern Med 1991;115:428-36. https://doi.org/10.7326/0003-4819-115-6-428
  11. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA 1996;275:134-41. https://doi.org/10.1001/jama.1996.03530260048030
  12. Torres A, Serra-Batlles J, Ferrer A, Jimenez P, Celis R, Cobo E, et al. Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am Rev Respir Dis 1991;144:312-8. https://doi.org/10.1164/ajrccm/144.2.312
  13. Almirall J, Bolibar I, Balanzo X, Gonzalez CA. Risk factors for community-acquired pneumonia in adults: a population-based case-control study. Eur Respir J 1999;13:349-55. https://doi.org/10.1183/09031936.99.13234999
  14. Garcia-Ordonez MA, Garcia-Jimenez JM, Paez F, Alvarez F, Poyato B, Franquelo M, et al. Clinical aspects and prognostic factors in elderly patients hospitalised for community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2001;20:14-9.
  15. Lim WS, Lewis S, Macfarlane JT. Severity prediction rules in community acquired pneumonia: a validation study. Thorax 2000;55:219-23. https://doi.org/10.1136/thorax.55.3.219
  16. Lim WS, van der Eerden MM, Laing R, Boersma WG, Kara- lus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-82. https://doi.org/10.1136/thorax.58.5.377
  17. Ramirez JA, Wiemken TL, Peyrani P, Arnold FW, Kelley R, Mattingly WA, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis 2017;65:1806-12. https://doi.org/10.1093/cid/cix647
  18. Chen Y, Stewart P, Dales R, Johansen H, Bryan S, Taylor G. In a retrospective study of chronic obstructive pulmonary disease inpatients, respiratory comorbidities were significantly associated with prognosis. J Clin Epidemiol 2005;58:1199- 205. https://doi.org/10.1016/j.jclinepi.2005.03.010
  19. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 2006;28:346-51. https://doi.org/10.1183/09031936.06.00131905
  20. Rello J, Rodriguez A, Torres A, Roig J, Sole-Violan J, Garnacho-Montero J, et al. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 2006;27:1210-6. https://doi.org/10.1183/09031936.06.00139305
  21. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005;128:2099-107. https://doi.org/10.1378/chest.128.4.2099
  22. Mullerova H, Chigbo C, Hagan GW, Woodhead MA, Miravitlles M, Davis KJ, et al. The natural history of commu- nity-acquired pneumonia in COPD patients: a population database analysis. Respir Med 2012;106:1124-33. https://doi.org/10.1016/j.rmed.2012.04.008
  23. Lin SH, Perng DW, Chen CP, Chai WH, Yeh CS, Kor CT, et al. Increased risk of community-acquired pneumonia in COPD patients with comorbid cardiovascular disease. Int J Chron Obstruct Pulmon Dis 2016;11:3051-8. https://doi.org/10.2147/COPD.S115137
  24. Feldman C, Viljoen E, Morar R, Richards G, Sawyer L, Goolam Mahomed A. Prognostic factors in severe community-acquired pneumonia in patients without co-morbid illness. Respirology 2001;6:323-30. https://doi.org/10.1046/j.1440-1843.2001.00352.x
  25. Community-acquired pneumonia in adults in British hospitals in 1982-1983: a survey of aetiology, mortality, prognos- tic factors and outcome. The British Thoracic Society and the Public Health Laboratory Service. Q J Med 1987;62:195-220. https://doi.org/10.1093/oxfordjournals.qjmed.a068093
  26. Fine MJ, Orloff JJ, Arisumi D, Fang GD, Arena VC, Hanusa BH, et al. Prognosis of patients hospitalized with community-acquired pneumonia. Am J Med 1990;88:1N-8N.
  27. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50. https://doi.org/10.1056/NEJM199701233360402
  28. Metlay JP, Fine MJ. Testing strategies in the initial management of patients with community-acquired pneumonia. Ann Intern Med 2003;138:109-18. https://doi.org/10.7326/0003-4819-138-2-200301210-00012
  29. Jiang HL, Chen HX, Liu W, Fan T, Liu GJ, Mao B. Is COPD associated with increased mortality and morbidity in hospitalized pneumonia? A systematic review and meta-analysis. Respirology 2015;20:1046-54. https://doi.org/10.1111/resp.12597
  30. Mammen MJ, Sethi S. Microbiome in chronic lung diseases. BRN Rev 2017;3:102-20.
  31. Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140:821-32. https://doi.org/10.1016/j.cell.2010.01.040
  32. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157(5 Pt 1):1418-22. https://doi.org/10.1164/ajrccm.157.5.9709032
  33. Rose MC, Voynow JA. Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev 2006;86:245-78. https://doi.org/10.1152/physrev.00010.2005
  34. Kesimer M, Ford AA, Ceppe A, Radicioni G, Cao R, Davis CW, et al. Airway mucin concentration as a marker of chronic bronchitis. N Engl J Med 2017;377:911-22. https://doi.org/10.1056/NEJMoa1701632
  35. Kirkham S, Kolsum U, Rousseau K, Singh D, Vestbo J, Thorn- ton DJ. MUC5B is the major mucin in the gel phase of sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;178:1033-9. https://doi.org/10.1164/rccm.200803-391OC
  36. Sibila O, Suarez-Cuartin G, Rodrigo-Troyano A, Fardon TC, Finch S, Mateus EF, et al. Secreted mucins and airway bacterial colonization in non-CF bronchiectasis. Respirology 2015;20:1082-8. https://doi.org/10.1111/resp.12595
  37. Sibila O, Garcia-Bellmunt L, Giner J, Rodrigo-Troyano A, Suarez-Cuartin G, Torrego A, et al. Airway mucin 2 is decreased in patients with severe chronic obstructive pulmonary disease with bacterial colonization. Ann Am Thorac Soc 2016;13:636-42. https://doi.org/10.1513/AnnalsATS.201512-797OC
  38. Braeken DC, Rohde GG, Franssen FM, Driessen JH, van Staa TP, Souverein PC, et al. Risk of community-acquired pneumonia in chronic obstructive pulmonary disease stratified by smoking status: a population-based cohort study in the United Kingdom. Int J Chron Obstruct Pulmon Dis 2017;12:2425-32. https://doi.org/10.2147/COPD.S138435
  39. Shukla SD, Muller HK, Latham R, Sohal SS, Walters EH. Platelet-activating factor receptor (PAFr) is upregulated in small airways and alveoli of smokers and COPD patients. Respirology 2016;21:504-10. https://doi.org/10.1111/resp.12709
  40. Shukla SD, Sohal SS, Mahmood MQ, Reid D, Muller HK, Walters EH. Airway epithelial platelet-activating factor receptor expression is markedly upregulated in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2014;9:853-61.
  41. Kc R, Shukla SD, Walters EH, O'Toole RF. Temporal upregulation of host surface receptors provides a window of opportunity for bacterial adhesion and disease. Microbiology 2017;163:421-30. https://doi.org/10.1099/mic.0.000434
  42. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008;359:2355-65. https://doi.org/10.1056/NEJMra0800353
  43. Wilkinson TM, Patel IS, Wilks M, Donaldson GC, Wedzicha JA. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:1090-5. https://doi.org/10.1164/rccm.200210-1179OC
  44. Clarridge JE 3rd. Impact of 16S rRNA gene sequence analysis for identification of bacteria on clinical microbiology and infectious diseases. Clin Microbiol Rev 2004;17:840-62. https://doi.org/10.1128/CMR.17.4.840-862.2004
  45. Sze MA, Dimitriu PA, Hayashi S, Elliott WM, McDonough JE, Gosselink JV, et al. The lung tissue microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185:1073-80. https://doi.org/10.1164/rccm.201111-2075OC
  46. Erb-Downward JR, Thompson DL, Han MK, Freeman CM, McCloskey L, Schmidt LA, et al. Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS One 2011;6:e16384. https://doi.org/10.1371/journal.pone.0016384
  47. Liapikou A, Polverino E, Ewig S, Cilloniz C, Marcos MA, Mensa J, et al. Severity and outcomes of hospitalised community-acquired pneumonia in COPD patients. Eur Respir J 2012;39:855-61. https://doi.org/10.1183/09031936.00067111
  48. El-Solh AA, Sikka P, Ramadan F, Davies J. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med 2001;163(3 Pt 1):645-51. https://doi.org/10.1164/ajrccm.163.3.2005075
  49. Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Nieder- man MS, et al. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002;162:1849- 58. https://doi.org/10.1001/archinte.162.16.1849
  50. Sibila O, Rodrigo-Troyano A, Shindo Y, Aliberti S, Restrepo MI. Multidrug-resistant pathogens in patients with pneumonia coming from the community. Curr Opin Pulm Med 2016;22:219-26. https://doi.org/10.1097/MCP.0000000000000263
  51. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730-54. https://doi.org/10.1164/ajrccm.163.7.at1010
  52. Global Initiative for Asthma. Global strategy for asthma management and prevention [Internet]. Global Initiative for Asthma; 2017 [cited 2017 Nov 10]. Available from: http://www.ginasthma.org/.
  53. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD [Internet]. Global Initiative for Chronic Obstructive Lung Disease; 2017 [cited 2017 Nov 10]. Available from: http://www.goldcopd.org/.
  54. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-56. https://doi.org/10.1016/S0140-6736(03)12459-2
  55. Nannini L, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007;(4):CD003794.
  56. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89. https://doi.org/10.1056/NEJMoa063070
  57. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:144-9. https://doi.org/10.1164/rccm.200602-244OC
  58. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26. https://doi.org/10.1164/rccm.200707-973OC
  59. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;176:162-6. https://doi.org/10.1164/rccm.200611-1630OC
  60. Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, et al. Efficacy and tolerability of budesonide/ formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:741-50. https://doi.org/10.1164/rccm.200904-0492OC
  61. Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallelgroup, randomised controlled trials. Lancet Respir Med 2013;1:210-23. https://doi.org/10.1016/S2213-2600(13)70040-7
  62. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013;68:1029-36. https://doi.org/10.1136/thoraxjnl-2012-202872
  63. DiSantostefano RL, Sampson T, Le HV, Hinds D, Davis KJ, Bakerly ND. Risk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic ob- structive pulmonary disease: a new-user cohort study. PLoS One 2014;9:e97149. https://doi.org/10.1371/journal.pone.0097149
  64. Festic E, Scanlon PD. Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease: a double effect of inhaled corticosteroids? Am J Respir Crit Care Med 2015;191:141-8. https://doi.org/10.1164/rccm.201409-1654PP
  65. Chen D, Restrepo MI, Fine MJ, Pugh MJ, Anzueto A, Metersky ML, et al. Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am J Respir Crit Care Med 2011;184:312-6. https://doi.org/10.1164/rccm.201012-2070OC
  66. Malo de Molina R, Mortensen EM, Restrepo MI, Copeland LA, Pugh MJ, Anzueto A. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia. Eur Respir J 2010;36:751-7. https://doi.org/10.1183/09031936.00077509
  67. Joo MJ, Au DH, Fitzgibbon ML, Lee TA. Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir Med 2010;104:246-52. https://doi.org/10.1016/j.rmed.2009.10.002
  68. Sellares J, Lopez-Giraldo A, Lucena C, Cilloniz C, Amaro R, Polverino E, et al. Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia. Am J Respir Crit Care Med 2013;187:1241-8. https://doi.org/10.1164/rccm.201209-1732OC
  69. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989;11:954-63. https://doi.org/10.1093/clinids/11.6.954
  70. Conesa D, Rello J, Valles J, Mariscal D, Ferreres JC. Invasive aspergillosis: a life-threatening complication of short-term steroid treatment. Ann Pharmacother 1995;29:1235-7. https://doi.org/10.1177/106002809502901209
  71. Wiest PM, Flanigan T, Salata RA, Shlaes DM, Katzman M, Lederman MM. Serious infectious complications of corticosteroid therapy for COPD. Chest 1989;95:1180-4. https://doi.org/10.1378/chest.95.6.1180
  72. Sibila O, Laserna E, Mortensen EM, Anzueto A, Restrepo MI. Effects of inhaled corticosteroids on pneumonia severity and antimicrobial resistance. Respir Care 2013;58:1489-94. https://doi.org/10.4187/respcare.02191
  73. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009;10:59. https://doi.org/10.1186/1465-9921-10-59
  74. Rodrigo GJ, Neffen H. A systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPD. Pulm Pharmacol Ther 2017;42:1- 6. https://doi.org/10.1016/j.pupt.2016.11.003
  75. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-9. https://doi.org/10.1183/09031936.03.00027003
  76. Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ram- achandran S, Martin UJ, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 2009;69:549-65. https://doi.org/10.2165/00003495-200969050-00004
  77. Janson C, Larsson K, Lisspers KH, Stallberg B, Stratelis G, Goike H, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ 2013;346:f3306. https://doi.org/10.1136/bmj.f3306
  78. Sharafkhaneh A, Southard JG, Goldman M, Uryniak T, Martin UJ. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med 2012;106:257-68. https://doi.org/10.1016/j.rmed.2011.07.020
  79. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;(3):CD010115.
  80. Halpin DM, Gray J, Edwards SJ, Morais J, Singh D. Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. Int J Clin Pract 2011;65:764-74. https://doi.org/10.1111/j.1742-1241.2011.02685.x
  81. Morjaria JB, Rigby A, Morice AH. Inhaled corticosteroid use and the risk of pneumonia and COPD exacerbations in the UPLIFT Study. Lung 2017;195:281-8. https://doi.org/10.1007/s00408-017-9990-8
  82. Edsbacker S, Wollmer P, Selroos O, Borgstrom L, Olsson B, Ingelf J. Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids? Pulm Pharmacol Ther 2008;21:247-58. https://doi.org/10.1016/j.pupt.2007.08.005
  83. Johnson M. Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy Clin Immunol 1996;97(1 Pt 2):169-76. https://doi.org/10.1016/S0091-6749(96)80217-X
  84. Dalby C, Polanowski T, Larsson T, Borgstrom L, Edsbacker S, Harrison TW. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. Respir Res 2009;10:104. https://doi.org/10.1186/1465-9921-10-104
  85. Garcha DS, Thurston SJ, Patel AR, Mackay AJ, Goldring JJ, Donaldson GC, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax 2012;67:1075-80. https://doi.org/10.1136/thoraxjnl-2012-201924
  86. Pragman AA, Kim HB, Reilly CS, Wendt C, Isaacson RE. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLoS One 2012;7:e47305. https://doi.org/10.1371/journal.pone.0047305
  87. Contoli M, Pauletti A, Rossi MR, Spanevello A, Casolari P, Marcellini A, et al. Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD. Eur Respir J 2017;50:1700451. https://doi.org/10.1183/13993003.00451-2017
  88. Talbot HK, Zhu Y, Chen Q, Williams JV, Thompson MG, Grif- fin MR. Effectiveness of influenza vaccine for preventing laboratory-confirmed influenza hospitalizations in adults, 2011-2012 influenza season. Clin Infect Dis 2013;56:1774-7. https://doi.org/10.1093/cid/cit124
  89. Sibila O, Suarez-Cuartin G, Rodrigo-Troyano A, Anzueto A. Corticosteroids and pneumonia in chronic obstructive pul- monary disease: a dual effect? BRN Rev 2015;1:105-15.
  90. Udell JA, Zawi R, Bhatt DL, Keshtkar-Jahromi M, Gaughran F, Phrommintikul A, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA 2013;310:1711-20. https://doi.org/10.1001/jama.2013.279206
  91. Centers for Disease Control and Prevention. Fluzone high-dose seasonal influenza vaccine [Internet]. Atlanta: Centers for Disease Control and Prevention; 2017 [cited 2016 Nov 30]. Available from: http://www.cdc.gov/flu/protect/vac-cine/qa_fluzone.htm.
  92. DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 2014;371:635-45. https://doi.org/10.1056/NEJMoa1315727
  93. Centers for Disease Control and Prevention. FLUAD flu vaccine with adjuvant [Internet]. Atlanta: Centers for Disease Control and Prevention; 2017 [cited 2016 Nov 30]. Available from: http://www.cdc.gov/flu/protect/vaccine/adjuvant. htm.
  94. Wongsurakiat P, Maranetra KN, Wasi C, Kositanont U, Dejsomritrutai W, Charoenratanakul S. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest 2004;125:2011-20. https://doi.org/10.1378/chest.125.6.2011
  95. Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;(1):CD002733.
  96. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331:778-84. https://doi.org/10.1056/NEJM199409223311206
  97. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009;58:1-52.
  98. Huang CL, Nguyen PA, Kuo PL, Iqbal U, Hsu YH, Jian WS. Influenza vaccination and reduction in risk of ischemic heart disease among chronic obstructive pulmonary elderly. Comput Methods Programs Biomed 2013;111:507-11. https://doi.org/10.1016/j.cmpb.2013.05.006
  99. Kobayashi M, Bennett NM, Gierke R, Almendares O, Moore MR, Whitney CG, et al. Intervals Between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2015;64:944-7. https://doi.org/10.15585/mmwr.mm6434a4
  100. Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Pat- terson S, Gault S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015;372:1114-25. https://doi.org/10.1056/NEJMoa1408544
  101. Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococ- cal polysaccharide vaccine. Vaccine 2013;31:3585-93. https://doi.org/10.1016/j.vaccine.2013.05.010
  102. Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, et al. Use of 13-valent pneumococcal conju- gate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ${\geq}$65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014;63:822-5.
  103. Alfageme I, Vazquez R, Reyes N, Munoz J, Fernandez A, Hernandez M, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006;61:189-95. https://doi.org/10.1136/thx.2005.043323
  104. Walters JA, Tang JN, Poole P, Wood-Baker R. Pneumococcal vaccines for preventing pneumonia in chronic obstruc- tive pulmonary disease. Cochrane Database Syst Rev 2017;1:CD001390.

Cited by

  1. Pharmacotherapy for chronic obstructive pulmonary disease vol.61, pp.9, 2018, https://doi.org/10.5124/jkma.2018.61.9.545
  2. Statin for Tuberculosis and Pneumonia in Patients with Asthma–Chronic Pulmonary Disease Overlap Syndrome: A Time-Dependent Population-Based Cohort Study vol.7, pp.11, 2018, https://doi.org/10.3390/jcm7110381
  3. Diagnostic value of urea, creatinine and blood parameters in patients with pneumonia diagnosed with chronic obstructive pulmonary disease vol.8, pp.None, 2018, https://doi.org/10.12688/f1000research.18538.1
  4. ILC2s Induce Adaptive Th2-Type Immunity in Acute Exacerbation of Chronic Obstructive Pulmonary Disease vol.2019, pp.None, 2018, https://doi.org/10.1155/2019/3140183
  5. The relationship between ventilator-associated pneumonia and chronic obstructive pulmonary disease: what is the current evidence? vol.38, pp.4, 2019, https://doi.org/10.1007/s10096-019-03486-2
  6. Optimizing Drug Therapies in Patients with COPD in the US Nursing Home Setting vol.36, pp.8, 2018, https://doi.org/10.1007/s40266-019-00680-x
  7. Risk of Pneumonia Associated With the Use of Inhaled Corticosteroids in Asthma vol.11, pp.6, 2019, https://doi.org/10.4168/aair.2019.11.6.760
  8. Preclinical Evaluation of the Antimicrobial-Immunomodulatory Dual Action of Xenohormetic Molecules against Haemophilus influenzae Respiratory Infection vol.9, pp.12, 2019, https://doi.org/10.3390/biom9120891
  9. A 21st Century Evil: Immunopathology and New Therapies of COVID-19 vol.11, pp.None, 2018, https://doi.org/10.3389/fimmu.2020.562264
  10. Interventions to Improve the Quality of Life of Patients with Chronic Obstructive Pulmonary Disease: A Global Mapping During 1990–2018 vol.17, pp.9, 2018, https://doi.org/10.3390/ijerph17093089
  11. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19) vol.167, pp.None, 2018, https://doi.org/10.1016/j.rmed.2020.105941
  12. A hypothesis on the role of the human immune system in covid-19 vol.143, pp.None, 2018, https://doi.org/10.1016/j.mehy.2020.110066
  13. Ratio and interconnections of functional fitness structure key components of elite combat athletes at the stage of maximum realization of individual capabilities vol.24, pp.5, 2018, https://doi.org/10.15561/20755279.2020.0505
  14. Comorbidities, COPD and COVID 19 vol.69, pp.2, 2018, https://doi.org/10.2478/pneum-2020-0014
  15. Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD vol.16, pp.None, 2018, https://doi.org/10.2147/copd.s291967
  16. Impact of Chronic Obstructive Pulmonary Disease on Infectious Complications and Mortality in Patients With Aneurysmal Subarachnoid Hemorrhage vol.12, pp.None, 2018, https://doi.org/10.3389/fneur.2021.723115
  17. Correlation between TNF-α -308 and +489 Gene Polymorphism and Acute Exacerbation of Chronic Obstructive Pulmonary Diseases vol.2021, pp.None, 2018, https://doi.org/10.1155/2021/6661281
  18. Vitamin D3 Attenuates Viral-Induced Inflammation and Fibrotic Responses in Bronchial Smooth Muscle Cells vol.12, pp.None, 2018, https://doi.org/10.3389/fimmu.2021.715848
  19. Association Between Aspirin Use and Decreased Risk of Pneumonia in Patients With Cardio-Cerebra-Vascular Ischemic Disease: A Population-Based Cohort Study vol.9, pp.None, 2021, https://doi.org/10.3389/fpubh.2021.625834
  20. Updated view on the treatment of chronic obstructive pulmonary disease in Korea vol.64, pp.3, 2018, https://doi.org/10.5124/jkma.2021.64.3.225
  21. Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact vol.26, pp.6, 2018, https://doi.org/10.1111/resp.14041
  22. Increased Medical and Implant-Related Complications in Total Hip Arthroplasty Patients With Underlying Chronic Obstructive Pulmonary Disease vol.36, pp.7, 2018, https://doi.org/10.1016/j.arth.2021.02.011
  23. Mechanisms, Pathophysiology and Currently Proposed Treatments of Chronic Obstructive Pulmonary Disease vol.14, pp.10, 2018, https://doi.org/10.3390/ph14100979
  24. Temperature-related effects on respiratory medical prescriptions in Spain vol.202, pp.None, 2018, https://doi.org/10.1016/j.envres.2021.111695
  25. Higher comorbidities and early death in hospitalized African-American patients with Covid-19 vol.21, pp.1, 2021, https://doi.org/10.1186/s12879-021-05782-9
  26. Low Levels of Influenza Vaccine Uptake among the Diabetic Population in Spain: A Time Trend Study from 2011 to 2020 vol.11, pp.1, 2018, https://doi.org/10.3390/jcm11010068